| symbol |
IMMY |
|---|
| 会社名 | Imprimis Pharmaceuticals Inc （インプリミス・ファ―マシュ―ティカルズ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Imprimis Pharmaceuticals Inc. (Imprimis) is engaged in the development production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company through its Imprimis Cares program owns markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas including ophthalmology urology otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas. インプリミス・ファ―マシュ―ティカルズは米国の製薬会社。眼科や創傷治療、泌尿器科薬物療法に焦点を当て開発に取り組む。独自の無菌および局所薬物製剤および関連技術の研究、開発、商業化に従事。点眼なしの眼科療法「Dropless」を開始。本社はカリフォルニア州サンディエゴ。
|
|---|
| 本社所在地 | 12264 El Camino Real Suite 350 San Diego CA 92130 USA |
|---|
| 代表者氏名 | Robert J. Kammer ロバート・J・カマー |
|---|
| 代表者役職名 | Chairman of the Board 取締役会会長 |
|---|
| 電話番号 | +1 858-704-4042 |
|---|
| 設立年月日 | 38718 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 128人 |
|---|
| url | www.imprimispharma.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/immy |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -5.47800 |
|---|
| 終値（lastsale） | 2.56 |
|---|
| 時価総額（marketcap） | 53886586.88 |
|---|
| 時価総額 | 時価総額（百万ドル） 70.09466 |
|---|
| 売上高 | 売上高（百万ドル） 33.06900 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 81.22766 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -9.45400 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Imprimis Pharmaceuticals Inc revenues increased 49% to $19.2M. Net loss decreased 72% to $991K. Revenues reflect License revenues increase of 25% to $20K. Lower net loss reflects Interest income (expense) net decrease of 14% to $1.3M (expense) Research and development decrease of 39% to $159K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.19 to -$0.05. |
|---|
IMMY - インプリミス・ファ―マシュ―ティカルズ （Imprimis Pharmaceuticals Inc.） インプリミス・ファ―マシュ―ティカルズ